BMS walks away from Orum's $100M degrader-antibody conjugate
Bristol Myers Squibb has terminated its $100 million deal with Orum Therapeutics after reviewing phase 1 data for the degrader-antibody conjugate.
Bristol Myers Squibb has decided to discontinue development of the degrader-antibody conjugate it obtained from Orum Therapeutics, a program that originally cost the pharma $100 million. The termination follows an internal review of phase 1 clinical data, though the specific findings were not disclosed.
The asset was part of a deal announced earlier, positioning BMS in the emerging class of degrader-antibody conjugates, which combine antibody targeting with protein degradation. With this decision, BMS forfeits the upfront payment and any potential milestones tied to the program.
Orum Therapeutics has not yet commented publicly on the termination. The move underscores the high-risk nature of early-stage oncology deals, where promising preclinical concepts can fail to translate in human trials.
More in Medicine & Biotech
Ebola Vaccine Trial Launches in DR Congo Outbreak Zone
Health workers in DR Congo have begun testing whether a vaccine designed for a different Ebola strain can protect against the current outbreak.
Beacon Gene Therapy for Rare Vision Loss Succeeds in Pivotal Trial
A pivotal trial of Beacon Therapeutics' gene therapy for X-linked retinitis pigmentosa improved visual acuity, clearing the path toward an FDA submission.
Alkermes orexin agonist shows early promise for ADHD
Early-stage data suggest Alkermes' orexin agonist could expand the drug class beyond sleep disorders into ADHD.
Telix to Buy ITM for $1.65B, Challenging Novartis in Radiopharma
The acquisition gives Telix a late-stage pipeline and supply network that could compete with Novartis' Lutathera.